Trial reportNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2013
Deep brain stimulation of the subthalamic nucleus, but not dopaminergic medication, improves proactive inhibitory control of movement initiation in Parkinson's disease.
Trial report in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson's disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial.Journal of neurology · 2023Trial
- Trial
- Trial
- Modulation of motor inhibition by subthalamic stimulation in obsessive-compulsive disorder.Translational psychiatry · 2016Trial
- Targeting impulsivity in Parkinson's disease using atomoxetine.Brain : a journal of neurology · 2014Trial
- Neurons of the human subthalamic nucleus engage with local delta frequency processes during action cancellation.Nature communications · 2026Article
- Hyperdirect projections from the supplementary motor area mediate subthalamic stimulation effects on movement initiation and inhibition in Parkinson's disease.Brain communications · 2026Article
- Cortical beta power modulation is asymmetric and reduced during movement execution and inhibition in Parkinson's disease.Neurobiology of disease · 2025Article
- Subthalamic Activity Is Associated With Proactive Inhibition in Parkinson's Disease Patients.The European journal of neuroscience · 2025Article
- Review
- A narrative review of the anatomy and function of the white matter tracts in language production and comprehension.Frontiers in human neuroscience · 2023Review
- Relationship among Connectivity of the Frontal Aslant Tract, Executive Functions, and Speech and Language Impairment in Children with Childhood Apraxia of Speech.Brain sciences · 2022Article
- The superior response speed of table tennis players is associated with proactive inhibitory control.PeerJ · 2022Article
- Reverse Visually Guided Reaching in Patients with Parkinson's Disease.Parkinson's disease · 2022Article
- Proactive inhibition is not modified by deep brain stimulation for Parkinson's disease: An electrical neuroimaging study.Human brain mapping · 2021Article
- The Human Basal Ganglia Mediate the Interplay between Reactive and Proactive Control of Response through Both Motor Inhibition and Sensory Modulation.Brain sciences · 2021Article
- Altered Inhibitory Mechanisms in Parkinson's Disease: Evidence From Lexical Decision and Simple Reaction Time Tasks.Frontiers in human neuroscience · 2021Article
- Attenuated NoGo-related beta desynchronisation and synchronisation in Parkinson's disease revealed by magnetoencephalographic recording.Scientific reports · 2019Article
- Laterality of the frontal aslant tract (FAT) explains externalizing behaviors through its association with executive function.Developmental science · 2019Article
- The frontal aslant tract (FAT) and its role in speech, language and executive function.Cortex; a journal devoted to the study of the nervous system and behavior · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Slowness in movement initiation is a cardinal feature of Parkinson's disease (PD) that is still poorly understood and unsuccessfully alleviated by standard therapies. Here, we raise this major clinical issue within the framework of a novel theoretical model that allows a better understanding of the basic mechanisms involved in movement initiation. This model assumes that movement triggering is inhibited by default to prevent automatic responses to unpredictable events. We investigated to which extent the top-down control necessary to release this locking state before initiating actions is impaired in PD and restored by standard therapies. We used a cue-target reaction time task to test both the ability to initiate fast responses to targets and the ability to refrain from reacting to cues. Fourteen patients with dopaminergic (DA) medication and 11 with subthalamic nucleus (STN) stimulation were tested on and off treatment, and compared with 14 healthy controls. We found evidence that patients withdrawn from treatment have trouble voluntarily releasing proactive inhibitory control; while DA medication broadly reduces movement initiation latency, it does not reinstate a normal pattern of movement initiation; and stimulation of the STN specifically re-establishes the efficiency of the top-down control of proactive inhibition. These results suggest that movement initiation disorders that resist DA medication are due to executive, not motor, dysfunctions. This conclusion is discussed with regard to the role the STN may play as an interface between non-DA executive and DA motor systems in cortico-basal ganglia loops.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.